Immunosuppressant Monitoring-Performance of the First Mass Spectrometry-Based Automated Clinical Analyzer Cascadion

被引:1
|
作者
Grote-Koska, Denis [1 ]
Czajkowski, Stefan [1 ]
Staaden, Antje [1 ]
Brand, Korbinian [1 ]
机构
[1] Hannover Med Sch, Inst Clin Chem, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
immunosuppressants; LC-MS; MS; automated analyzer; CYCLOSPORINE-A; TACROLIMUS; ASSAY;
D O I
10.1097/FTD.0000000000001051
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background:Automatic analyzers simplify processes and may help improve standardization. The first automated analyzer based on mass spectrometry is available and offers a panel for monitoring cyclosporin A, tacrolimus, sirolimus, and everolimus. Method comparisons and evaluation tests are presented to verify the capability of the Cascadion system for use in a clinical laboratory.Methods:Sample preparation and measurements were performed using the Cascadion clinical analyzer. More than 1000 measurement values of patient samples were compared with an in vitro diagnostic-certified assay run on a liquid chromatography tandem mass spectrometry instrument. Precision and accuracy were determined using commercial quality control and external quality assessment (EQA) samples.Results:A good correlation between the 2 instruments was observed (Pearson correlation r = 0.956-0.996). Deming regression revealed 95% confidence intervals of slopes and intercepts covering the values 1 and 0, for sirolimus and everolimus, respectively, indicating equivalence of both measuring systems. However, for cyclosporin A, a bias was observed and confirmed using a Bland-Altman plot (-9.1%). Measurement repeatability and intermediate measurement precision were appropriate showing coefficients of variation of 0.9%-6.1% and 2.0%-5.3%, respectively. Accuracy according to internal quality controls was 85%-111% and 81%-100% in the EQA samples of Reference Institute of Bioanalytics and Laboratory of the Government Chemist, respectively. High robustness was found with regard to the linearity of the calibration lines (linear regression coefficient r(2) > 0.99). Carryover was negligible (0.1%).Conclusions:The Cascadion automatic analyzer produced convincing results in the measurement of patient, control, and EQA samples. The throughput was sufficient for routine use. Overall, it can be used as an alternative to open liquid chromatography tandem mass spectrometry instruments for immunosuppressant monitoring, simplifying processes without the need for specially trained personnel.
引用
收藏
页码:14 / 19
页数:6
相关论文
共 50 条
  • [1] Profiling of stratum corneum lipids by an HPLC/mass spectrometry-based, automated lipid analyzer
    Tojo, Hiromasa
    [J]. CHEMISTRY AND PHYSICS OF LIPIDS, 2007, 149 : S72 - S72
  • [2] Mass spectrometry-based clinical proteomics
    Pusch, W
    Flocco, MT
    Leung, SM
    Thiele, H
    Kostrzewa, M
    [J]. PHARMACOGENOMICS, 2003, 4 (04) : 463 - 476
  • [3] Performance of the Cascadion(TM) SM, a fully automated liquid chromatography mass spectrometry analyzer, for the measurement of total 25-hydroxy vitamin D
    Hetu, Pierre-Olivier
    Athot, Guylaine
    El Manaa, Karama
    Albert, Caroline
    [J]. CLINICAL BIOCHEMISTRY, 2022, 109 : 104 - 105
  • [4] Automated workflow composition in mass spectrometry-based proteomics
    Palmblad, Magnus
    Lamprecht, Anna-Lena
    Ison, Jon
    Schwammle, Veit
    [J]. BIOINFORMATICS, 2019, 35 (04) : 656 - 664
  • [5] Mass spectrometry-based phosphoproteomics in clinical applications
    Wu, Xiaofeng
    Liu, Yi-Kai
    Iliuk, Anton B.
    Tao, W. Andy
    [J]. TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2023, 163
  • [6] Mass spectrometry-based clinical proteomics - a revival
    Pauwels, Jarne
    Gevaert, Kris
    [J]. EXPERT REVIEW OF PROTEOMICS, 2021, 18 (06) : 411 - 414
  • [7] Clinical potential of mass spectrometry-based proteogenomics
    Bing Zhang
    Jeffrey R. Whiteaker
    Andrew N. Hoofnagle
    Geoffrey S. Baird
    Karin D. Rodland
    Amanda G. Paulovich
    [J]. Nature Reviews Clinical Oncology, 2019, 16 : 256 - 268
  • [8] Clinical potential of mass spectrometry-based proteogenomics
    Zhang, Bing
    Whiteaker, Jeffrey R.
    Hoofnagle, Andrew N.
    Baird, Geoffrey S.
    Rodland, Karin D.
    Paulovich, Amanda G.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (04) : 256 - 268
  • [9] Automated Composition of Scientific Workflows in Mass Spectrometry-Based Proteomics
    Lamprecht, Anna-Lena
    Palmblad, Magnus
    Ison, Jon
    Schwammle, Veit
    [J]. 2018 IEEE 14TH INTERNATIONAL CONFERENCE ON E-SCIENCE (E-SCIENCE 2018), 2018, : 360 - 361
  • [10] Advances in mass spectrometry-based clinical biomarker discovery
    Crutchfield, Christopher A.
    Thomas, Stefani N.
    Sokoll, Lori J.
    Chan, Daniel W.
    [J]. CLINICAL PROTEOMICS, 2016, 13